Helena Linardou
Helena Linardou is an expert in Oncology at Metropolitan Hospital (Greece). As of October 2026, ScienceLeadR ranks Helena Linardou in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Helena Linardou has authored 175 publications, the most recent in 2026, and is an investigator in 34 clinical trials, 19 of them ongoing. SLR score: 1,221 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pulmonology - Biochemistry - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1994 - 2026
Number : 175
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Integrated Molecular, Clinicopathological and Immune Profiling of Non-Small Cell Lung Cancer: The MONREPOS Hellenic Cooperative Oncology Group (HeCOG) Study (HE_2TR/13). PMID 42883968 — cells, genes, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, prognosis | Int J Mol Sci | 2026 | 0 |
| Toward personalized shared decision-making: a pilot study on an individualized patient decision aid. PMID 42830559 — pilot projects, pilots, lung, decision making, shared, oncologists, communication, neoplasms, decision making, lung neoplasms, patient preference, physicians | Eur J Cancer Prev | 2026 | 0 |
| Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS G12C mutations. PMID 42745627 — cells, language, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, mutation | Future Oncol | 2026 | 0 |
| Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC. PMID 42733093 — lung, carcinoma, non-small-cell lung, deep learning, learning, artificial intelligence | Nat Med Top journal | 2026 | 1 |
| Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC. PMID 42532338 — research design, neoplasms, carcinoma, non-small-cell lung, uncertainty, therapeutics, rna | J Thorac Oncol | 2026 | 0 |
Clinical Studies 34
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
19 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases 2023-507494-18-00 — oncogenes, proto-oncogenes, cells, genes, lung, receptor protein-tyrosine kinases, safety, neoplasms, gene rearrangement, carcinoma, non-small-cell lung, central nervous system, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, nervous system, crizotinib | Phase 3 | Active not recruiting | 2021 |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non Squamous Non Small Cell Lung Cancer (NSCLC) 2023-505749-14-00 — cells, lung, docetaxel, neoplasms, carcinoma, non-small-cell lung, drug-related side effects and adverse reactions, lung neoplasms, small cell lung carcinoma | Phase 3 | Recruiting | 2022 |
| A proof of concept study to evaluate treatments efficacy by monitoring Minimal Residual Disease using ctDNA in HR positive HER2 negative early breast cancer population 2023-505661-89-00 — epidermal growth factor, growth, breast neoplasms, neoplasms, hormones, proof of concept study, receptors, growth factor, breast, neoplasm, residual, therapeutics | Phase 2 | Recruiting | 2024 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First line Treatment of PD L1 high Metastatic Non small Cell Lung Cancer 2024-517780-24-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics | Phase 3 | Recruiting | 2025 |
| A Study to Learn About the Study Medicine Called PF 08046054 SGNPDL1V Versus Docetaxel in Adult Participants with Previously treated Programmed Cell Death Ligand 1 (PD L1) Positive Non small cell Lung Cancer (NSCLC) 2025-521281-97-00 — cells, lung, docetaxel, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, ligands, cell death | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map